Alto Neuroscience has initiated a Phase 2 study of ALTO-203, a PDE4 inhibitor targeted at patients with major depressive disorder (MDD) and anhedonia. This follows positive Phase 1 data for the transdermal formulation of ALTO-101. The improved drug delivery system significantly increased exposure while reducing tolerability issues compared to oral administration.
Phase 2b studies for ALTO-100 and ALTO-300, both targeting MDD, also progress steadily. ALTO-100 is a first-in-class small molecule that enhances neural plasticity, while ALTO-300 is an adjunctive treatment for patients with insufficient response to antidepressants.
Alto’s financial position remains strong, with approximately $206 million expected to support operations into 2027.
•ALTO-100: Ongoing Phase 2b study in MDD patients with a cognitive biomarker. Topline data is expected in the second half of 2024.
•ALTO-300: Ongoing Phase 2b study in MDD patients with an EEG biomarker. Topline data is expected in the first half of 2025.
•ALTO-101: Novel PDE4 inhibitor in Phase 1 development for CIAS. Positive Phase 1 results demonstrated improved drug exposure and tolerability. A proof-of-concept study in schizophrenia is planned.
Alto Neuroscience remains dedicated to developing personalized therapies for brain disorders. The company’s commitment is evident in its advancements across its clinical pipeline and its ongoing execution of clinical trials. Alto anticipates reporting results from its depression studies in the coming year and looks forward to the potential transformative impact of its treatments for patients in need.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
